In patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)

Regular molecular monitoring is associated with a significantly lower risk of disease progression1

  • In a retrospective analysis, 402 Ph+ CML-CP patients were followed for at least 3 years after initiation of therapy1
  • Data were collected on the date of progression and the date of death1
Regular molecular monitoring in CML Regular molecular monitoring in CML

Regular molecular monitoring can detect a rise in BCR-ABL transcripts, which has been shown to be associated with kinase domain mutations, poor adherence, and other interruptions in therapy1

  • Monitoring 3 to 4 times per year provides information on treatment response that can inform clinical decisions. Appropriate and timely interventions could prevent further disease progression and improve long-term outcomes1

Regular molecular monitoring can detect a rise in BCR-ABL transcripts, which has been shown to be associated with kinase domain mutations, poor adherence, and other interruptions in therapy1

Routine molecular monitoring supports successful disease management

National Comprehensive Cancer Network® (NCCN®) recommends IS RQ-PCR testing at diagnosis and every 3 months after initiating treatment2

IS molecular monitoring every 3 months serves as a crucial early warning system for patients with suboptimal response3

NCCN® molecular monitoring recommendations NCCN® molecular monitoring recommendations
  • IS RQ-PCR can be performed on peripheral blood for routine monitoring2

IS molecular monitoring every 3 months serves as a crucial early warning system for patients with suboptimal response3

The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

CP, chronic phase; IS, International Scale; RQ-PCR, real-time quantitative polymerase chain reaction; CCyR, complete cytogenetic response.

References: 1. Goldberg SL, Chen L, Guerin A, et al. Curr Med Res Opin. 2013;29(9):1075-1082. 2. Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.2.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed March 1, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. Akard LP, Wang YL. Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. Clin Lymphoma Myeloma Leuk. 2011;11(5):385-395.